Sucampo Pharmaceuticals, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of drugs based on prostones. It develops prostones for the treatment of gastrointestinal, respiratory, vascular, and central nervous system diseases and disorders. The company markets AMITIZA (lubiprostone) for chronic idiopathic constipation in adults in the United States and is developing the drug for the treatment of multiple constipation-related gastrointestinal disorders. Sucampo Pharmaceuticals is also completed two pivotal Phase III clinical trials of AMITIZA for the treatment of irritable bowel syndrome with constipation. In addition, it is developing other prostone compounds, including Cobiprostone, which is under Phase II clinical trial for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, portal hypertension, non-alcoholic fatty liver disease, disorders associated with cystic fibrosis, and chronic obstructive pulmonary disease; and SPI-017, which is under preclinical trial, for the treatment of peripheral arterial and vascular disease and central nervous system disorders, as well as involves in the development an oral formulation of SPI-017 for the treatment of Alzheimer's disease. Further, the company engages in the Phase III pivotal clinical trial of AMITIZA for the treatment of opioid-induced bowel dysfunction. Sucampo Pharmaceuticals has a collaboration and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize AMITIZA for chronic idiopathic constipation, irritable bowel syndrome with constipation, opioid-induced bowel dysfunction, and other gastrointestinal indications in the United States and Canada. The company was founded in 1996 and is headquartered in Bethesda, Maryland.